Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Japanese drug major Astellas has appointed Rodrigo Fernandez executive director, international business, with responsibility for managing business in Latin America outside of Brazil. 29 April 2016
Ireland-based Perrigo has announced that Sharon Kochan will lead the expansion of the company’s branded consumer healthcare (BCH) segment. 28 April 2016
US biotech major Biogen has lured Michael Ehlers, a senior vice president at pharma giant Pfizer, as its executive vice president, Research and Development. 27 April 2016
Troubled Valeant Pharmaceuticals has named Joseph Papa as its new chief executive, calling him an appointment with “an ethical approach.” 25 April 2016
Maya Martinez-Davis has been appointed as global head of oncology of the biopharma business of German pharma giant Merck KGaA, it was announced on Thursday. 14 April 2016
Starboard Value, a privately owned hedge fund sponsor, has written a strongly-worded letter to US specialty drugmaker Depomed, in which the investor now owns almost 10% of the shares. 11 April 2016
US biotech major Biogen has recruited former Merck & Co executive Michel Vounatsos as the company’s executive vice president and chief commercial officer, effective April 18, 2016. 30 March 2016
Japanese drugmaker Sosei Group has announced that Peter Bains will take over as both chief operating officer and chief executive in the next three months. 22 March 2016
Valeant Pharmaceuticals International today announced that it has initiated a search for a new chief executive officer, and appointed William Ackman, chief executive of hedge fund Pershing Square Management, to its board of directors. 21 March 2016
US clinical-stage cancer drug develop Threshold Pharmaceuticals has announced the appointment of Stewart Kroll as chief operating officer. 21 March 2016
The chief executive of UK pharma major GlaxoSmithKline, Sir Andrew Witty, will retire in March next year, the company announced on Thursday. 17 March 2016
US clinical-stage biotechnology company Rigel Pharmaceuticals has appointed Anne-Marie Duliege as its new chief medical officer, it has been announced. 9 March 2016
Canadian drugmaker Valeant Pharmaceuticals has confirmed that executive vice president, company group chairman, Deb Jorn, has resigned from the company with immediate effect. 4 March 2016